S309-CAR-NK cells bind the Omicron variants in vitro and reduce SARS-CoV-2 viral loads in humanized ACE2-NSG mice
Journal of Virology · 2024
DOI: 10.1128/jvi.00038-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Minh Tuyet Ma und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Immunology, and Laboratory Medicine, South Orange Avenue, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Killer Cells, Natural, Angiotensin-Converting Enzyme 2, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Recent progress on chimeric antigen receptor (CAR)-NK cells has shown promising results in treating CD19-positive lymphoid tumors with minimal toxicities [including graft versus host disease (GvHD) and cytokine release syndrome (CRS) in clinical trials. Nevertheless, the use of CAR-NK cells in combating viral infections has not yet been fully explored. Previous studies have shown that CAR-NK cells expressing S309 single-chain fragment variable (scFv), hereinafter S309-CAR-NK cells, can bind to SARS-CoV-2 wildtype pseudotyped virus (PV) and effectively kill cells expressing wild-type spike protein in vitro . In this study, we further demonstrate that the S309-CAR-NK cells can bind to different SARS-CoV-2 variants, including the B.1.617.2 (Delta), B.1.621 (Mu), and B.1.1.529 (Omicron) variants in vitro . We also show that S309-CAR-NK cells reduce virus loads in the NOD/SCID gamma (NSG) mice expressing the human angiotensin-converting enzyme 2 (hACE2) receptor challenged with SARS-CoV-2 wild-type (strain USA/WA1/2020). Our study demonstrates the potential use of S309-CAR-NK cells for inhibiting infection by SARS-CoV-2 and for the potential treatment of COVID-19 patients unresponsive to otherwise currently available therapeutics. IMPORTANCE Chimeric antigen receptor (CAR)-NK cells can be “off-the-shelf” products that treat various diseases, including cancer, infections, and autoimmune diseases. In this study, we engineered natural killer (NK) cells to express S309 single-chain fragment variable (scFv), to target the Spike protein of SARS-CoV-2, hereinafter S309-CAR-NK cells. Our study shows that S309-CAR-NK cells are effective against different SARS-CoV-2 variants, including the B.1.617.2 (Delta), B.1.621 (Mu), and B.1.1.529 (Omicron) variants. The S309-CAR-NK cells can (i) directly bind to SARS-CoV-2 pseudotyped virus (PV), (ii) competitively bind to SARS-CoV-2 PV with 293T cells expressing the human angiotensin-converting enzyme 2 (hACE2) receptor (293T-hACE2 cells), (iii) specifically target and lyse A549 cells expressing the spike protein, and (iv) significantly reduce the viral loads of SARS-CoV-2 wild-type (strain USA/WA1/2020) in the lungs of NOD/SCID gamma (NSG) mice expressing hACE2 (hACE2-NSG mice). Altogether, the current study demonstrates the potential use of S309-CAR-NK immunotherapy as an alternative treatment for COVID-19 patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Immunology, and Laboratory Medicine, South Orange Avenue, Newark, New Jersey, USA.
- School of Graduate Studies, Rutgers Biomedical and Health Sciences, Newark, New Jersey, USA.
- Center for Immunity and Inflammation, New Jersey Medical School, Rutgers-The State University of New Jersey, Newark, New Jersey, USA.
- Public Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
- Department of Anatomy and Neurobiology, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
- Center for Retrovirus Research, The Ohio State University, Columbus, Ohio, USA.
ORCID-Profile: Minh Tuyet Ma, Qingkui Jiang, Saiaditya Badeti, Xuening Wang, Salvatore A E Marras, Sanjay Tyagi, Preeti Bharaj, Shan-Lu Liu, Lanbo Shi, Dongfang Liu
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- NIAID NIH HHS
- HHS | NIH | National Heart, Lung, and Blood Institute
- HHS | NIH | National Institute of Allergy and Infectious Diseases
- HHS | NIH | National Cancer Institute
- New Jersey Commission on Cancer Research
- Anonymous private donor to The Ohio State University
Zitieren
APA
Ma, M. T., Jiang, Q., Chen, C. H., Badeti, S., Wang, X., Zeng, C., Evans, D., Bodnar, B., Marras, S. A. E., Tyagi, S., Bharaj, P., Yehia, G., Romanienko, P., Hu, W., Liu, S. L., Shi, L., & Liu, D. (2024). S309-CAR-NK cells bind the Omicron variants in vitro and reduce SARS-CoV-2 viral loads in humanized ACE2-NSG mice. Journal of Virology. https://doi.org/10.1128/jvi.00038-24
Vancouver
Ma MT, Jiang Q, Chen CH, Badeti S, Wang X, Zeng C, et al. S309-CAR-NK cells bind the Omicron variants in vitro and reduce SARS-CoV-2 viral loads in humanized ACE2-NSG mice. Journal of Virology. 2024. doi:10.1128/jvi.00038-24
BibTeX
@article{Ma2024,
author = {Ma, Minh Tuyet and Jiang, Qingkui and Chen, Chih-Hsiung and Badeti, Saiaditya and Wang, Xuening and Zeng, Cong and Evans, Deborah and Bodnar, Brittany and Marras, Salvatore A E and Tyagi, Sanjay and Bharaj, Preeti and Yehia, Ghassan and Romanienko, Peter and Hu, Wenhui and Liu, Shan-Lu and Shi, Lanbo and Liu, Dongfang},
title = {S309-CAR-NK cells bind the Omicron variants in vitro and reduce SARS-CoV-2 viral loads in humanized ACE2-NSG mice},
journal = {Journal of Virology},
year = {2024},
doi = {10.1128/jvi.00038-24}
}
EUVIMED